Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Felix Gerhard Maria Dietlein, M.D., Ph.D.


This page shows the publications Felix Dietlein has written about Lung Neoplasms.
Connection Strength

  1. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep. 2020 04 28; 31(4):107568.
    View in: PubMed
    Score: 0.039
  2. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018 08 01; 78(15):4270-4281.
    View in: PubMed
    Score: 0.034
  3. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene. 2018 05; 37(20):2746-2756.
    View in: PubMed
    Score: 0.033
  4. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget. 2015 Nov 17; 6(36):38458-68.
    View in: PubMed
    Score: 0.029
  5. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015 Jul 02; 162(1):146-59.
    View in: PubMed
    Score: 0.028
  6. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2014 Feb; 4(2):246-57.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.